2021 Revenues ($USD) : $30,117,000,000
2021 R&D spend : $2,493,000,000
2021 Number of Employees : 90,000
Fiscal Year End : 4/30/2021
Key People : Geoff Martha, chair and CEO; Noel Colón, SVP, chief quality officer; Alex Gu, SVP and president, greater China; Richard Kuntz, SVP, chief medical and scientific officer; Chris Lee, SVP and president, Asia Pacific; Brad Lerman, SVP, general counsel and corporate secretary (retiring Dec. 31, 2021); John Liddicoat, EVP and president, Americas region; Laura Mauri, SVP, chief clinical and regulatory officer; Torod Neptune, SVP and chief communications officer; Karen Parkhill, EVP and CFO; Sean Salmon, EVP, president of the cardiovascular portfolio and diabetes operating unit; Greg Smith, EVP, global operations and supply chain; Carol Surface, EVP and chief human resources officer; Rob Ten Hoedt, EVP and president, Europe, Middle East, and Africa region; Brett Wall, EVP and president, neuroscience portfolio; Bob White, EVP and president, medical surgical portfolio.

About the company: Founded in 1949 by legendary medtech figure Earl Bakken, Medtronic began as a repair shop for medical equipment before a foray into pacemakers. Among the company’s big splashes in the space was the 2015 acquisition of Covidien, which became the largest medtech acquisition ever at $42.9 billion and placed Medtronic’s official base in Dublin, Ireland, even as it continues to be run operationally out of Minnesota. Other major acquisitions by Medtronic include Mazor Robotics and its robotic surgical platform, Titan Spine and its orthopedic implants, MiniMed and its insulin pumps, and more. Today, Medtronic’s offerings range from neurostimulation devices to replacement heart valves, along with insulin pumps and robotic surgery platforms, plus more across 20 operating units that a massive reorganization effort created at the end of 2020. This year, the company has continued to move forward in surgical robotics, winning European approval for the Hugo robot-assisted surgery platform and initiating the Canadian launch of its Mazor X system for robotic-guided spine surgery. It bought intellectual property regarding insulin pumps from the Alfred E. Mann Foundation and is reportedly set to buy insulin pump maker Triple Jump out of Israel. Medtronic also received FDA approval for its next-generation Evolut transcatheter aortic valve replacement (TAVR) platform while it will continue the clinical trial for its Symplicity Spyral renal denervation (RDN) system as it looks toward an eventual FDA nod.  –SW